Research progress of Yttrium-90 in the treatment of unresectable and chemotherapy-tolerant colorectal liver metastasis
10.3760/cma.j.issn.1673-9752.2016.02.018
- VernacularTitle:钇90治疗不可切除且化疗耐受结直肠癌肝转移的研究进展
- Author:
Zhongzhi JIA
;
Chunfu ZHU
;
Xihu QIN
- Publication Type:Journal Article
- Keywords:
Colorectal neoplasms;
Liver metastases;
Yttrium-90;
Therapy
- From:
Chinese Journal of Digestive Surgery
2016;15(2):200-202
- CountryChina
- Language:Chinese
-
Abstract:
Colorectal liver metastasis (CRLM) is a common liver metastatic tumor with poor prognosis.It was very difficult to treat patients with unresectable and chemotherapytolerant CRLM.With the tumor control rate ranging from 63％ to 78％,Yttrium-90 is both safe and effective in treating unresectable and chemotherapy-tolerant CRLM.The median survival time is 10.5 months,and the 1-,2-,3-year overall survival rates of patients are 44％,20％ and 14％ respectively.For a certain portion of patients,Yttrium-90 has distinct advantages over mo lecular targeted drugs and other local minimally invasive treatment.Though Yttrium-90 treatment has showed certain curative effect,its safety and effectiveness require further confirmation through multi-center randomized controlled trial.
